FR2845993B1 - Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques - Google Patents

Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques

Info

Publication number
FR2845993B1
FR2845993B1 FR0212886A FR0212886A FR2845993B1 FR 2845993 B1 FR2845993 B1 FR 2845993B1 FR 0212886 A FR0212886 A FR 0212886A FR 0212886 A FR0212886 A FR 0212886A FR 2845993 B1 FR2845993 B1 FR 2845993B1
Authority
FR
France
Prior art keywords
pde5
compositions containing
smooth muscle
therapeutic uses
containing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0212886A
Other languages
English (en)
Other versions
FR2845993A1 (fr
Inventor
Claire Renee Jeanne Mo Lugnier
Tcheudji Jacques Kameni
Luc Lebeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Louis Pasteur Strasbourg I
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Louis Pasteur Strasbourg I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Louis Pasteur Strasbourg I filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR0212886A priority Critical patent/FR2845993B1/fr
Priority to PCT/FR2003/003017 priority patent/WO2004035584A1/fr
Priority to AU2003288318A priority patent/AU2003288318A1/en
Publication of FR2845993A1 publication Critical patent/FR2845993A1/fr
Application granted granted Critical
Publication of FR2845993B1 publication Critical patent/FR2845993B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
FR0212886A 2002-10-16 2002-10-16 Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques Expired - Fee Related FR2845993B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR0212886A FR2845993B1 (fr) 2002-10-16 2002-10-16 Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
PCT/FR2003/003017 WO2004035584A1 (fr) 2002-10-16 2003-10-13 Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
AU2003288318A AU2003288318A1 (en) 2002-10-16 2003-10-13 Pharmaceutical compounds specifically inhibiting smooth muscle pde5, pharmaceutical compositions containing same and therapeutic uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0212886A FR2845993B1 (fr) 2002-10-16 2002-10-16 Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques

Publications (2)

Publication Number Publication Date
FR2845993A1 FR2845993A1 (fr) 2004-04-23
FR2845993B1 true FR2845993B1 (fr) 2005-02-11

Family

ID=32050450

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0212886A Expired - Fee Related FR2845993B1 (fr) 2002-10-16 2002-10-16 Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques

Country Status (3)

Country Link
AU (1) AU2003288318A1 (fr)
FR (1) FR2845993B1 (fr)
WO (1) WO2004035584A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202043234A (zh) 2019-01-24 2020-12-01 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
AR123034A1 (es) * 2020-07-23 2022-10-26 Prometheus Biosciences Inc Agentes terapéuticos dirigidos a gpr35

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2296014A1 (fr) * 1997-07-03 1999-01-14 Frank W. Hobbs Heterocycles aryl- et arylamino-substitues utilises comme antagonistes de l'hormone corticotrope
CA2295616C (fr) * 1997-07-09 2009-05-12 Christian Georg Stief Utilisation d'inhibiteurs de la phosphodiesterase dans le traitement de maladies de la prostate
DE19838705A1 (de) * 1998-08-26 2000-03-02 Bayer Ag Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one

Also Published As

Publication number Publication date
WO2004035584A1 (fr) 2004-04-29
AU2003288318A8 (en) 2004-05-04
AU2003288318A1 (en) 2004-05-04
FR2845993A1 (fr) 2004-04-23

Similar Documents

Publication Publication Date Title
EP1615623A4 (fr) Formes de doses orales de resistance a l'abus et son procede d'utilisation
ATE464049T1 (de) Pharmazeutische kombinationen von hydrocodon und naltrexon
IS7552A (is) Bensótengdar heteróarýl amíð afleiður af þíenópýridíni, gagnlegar sem meðferðarmiðlar, lyfjasamsetningar sem innihalda þær og aðferðir við notkun þeirra
EA200501586A1 (ru) Фармацевтические продукты
PL357856A1 (en) Pharmaceutical granules containing tamsulozine and method of their manufacture
PL374832A1 (en) Novel substituted benzimidazole dosage forms and method of using same
EP1483277A4 (fr) Conjugues de composes biologiquement actifs, procedes de preparation et d'utilisation, et formulation et applications pharmaceutiques
HK1088543A1 (en) Pharmaceutical compositions and dosage forms of thalidomide
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
HK1083835A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
EP1660043A4 (fr) Preparation a liberation immediate de compositions pharmaceutiques labiles en milieu acide
AU2003215245A8 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
HUP0203813A3 (en) Aminobenzophenones as inhibitors of il-1betha and tnf-alpha, pharmaceutical compositions containing them and their use
IL164217A0 (en) Pharmaceutical compositions containing water-soluble propofol and methods of administering same
HK1066459A1 (en) Pharmaceutical dosage form and method of making
FR2834459B1 (fr) Agent microbicide et composition de traitement cosmetique le contenant
IL162937A0 (en) Pravastatin pharmaceutical formulations and methods of their use
ZA200500203B (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
PL361518A1 (en) Application of substance and pharmaceutical composition
DE60137069D1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
IL163959A (en) Derivatives of phenyl-sulfonylamino- benzoic acid and pharmaceutical compositions comprising them
EP1849468A3 (fr) Composition pharmaceutique comprenant un inhibiteur de PDE4 ou PDE3/4 et un antagoniste du recepteur d'histamine
FR2845993B1 (fr) Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
FR2846327B1 (fr) Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
IS6437A (is) Ný setin pýrazóló [4,3-e]díazepín lyfjasamsetningar sem innihalda þau, notkun sem læknandi afurðir og aðferðir við framleiðslu þeirra

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20060630